Taylor & Francis Group
Browse

Harm reduction for the treatment of patients with severe injection-related infections: description of the Jackson SIRI Team

dataset
posted on 2021-11-02, 11:20 authored by David P. Serota, Hansel E. Tookes, Belén Hervera, Babley M. Gayle, Cara R. Roeck, Edward Suarez, David W. Forrest, Michael A. Kolber, Tyler S. Bartholomew, Allan E. Rodriguez, Susanne Doblecki-Lewis

Hospitalizations for severe injection-related infections (SIRI), such as endocarditis, osteomyelitis, and skin and soft tissue infections (SSTI) are increasingly common. People who inject drugs (PWID) experiencing SIRIs often receive inadequate substance use disorder (SUD) treatment and lack of access to harm reduction services. This translates into lengthy hospitalizations with high rates of patient-directed discharge, readmissions, and post-hospitalization mortality. The purpose of this study was to describe the development of an integrated “SIRI Team” and its initial barriers and facilitators to success.

The Jackson SIRI Team was developed to improve both hospital and patient-level outcomes for individuals hospitalized with SIRIs at Jackson Memorial Hospital, a 1550-bed public hospital in Miami, Florida, United States. The SIRI Team provides integrated infectious disease and SUD treatment across the healthcare system starting from the inpatient setting and continuing for 90-days post-hospital discharge. The team uses a harm reduction approach, provides care coordination, focuses on access to medications for opioid use disorder (MOUD), and utilizes a variety of infection and addiction treatment modalities to suit each individual patient.

Over the initial 8-months of the SIRI Team, 21 patients were treated with 20 surviving until discharge. Infections included osteomyelitis, endocarditis, bacteraemia/fungemia, SSTIs, and septic arthritis. All patients had OUD and 95% used stimulants. All patients were discharged on MOUD and 95% completed their prescribed antibiotic course. At 90-days post-discharge, 25% had been readmitted and 70% reported taking MOUD.

A model of integrated infectious disease and SUD care for the treatment of SIRIs has the potential to improve infection and addiction outcomes. Providing attentive, patient-centered care, using a harm reduction approach can facilitate engagement of this marginalized population with the healthcare system.KEY MESSAGES

Integrated infectious disease and addiction treatment is a novel approach to treating severe injection-related infections.

Harm reduction should be applied to treating patients with severe injection-related infections with a goal of facilitating antibiotic completion, remission from substance use disorder, and reducing hospital readmissions.

Integrated infectious disease and addiction treatment is a novel approach to treating severe injection-related infections.

Harm reduction should be applied to treating patients with severe injection-related infections with a goal of facilitating antibiotic completion, remission from substance use disorder, and reducing hospital readmissions.

Funding

Research reported in this publication was supported by the Miami Centre for AIDS Research (CFAR) at the University of Miami Miller School of Medicine of the National Institutes of Health under award number P30AI1073961, which is supported by the following NIH Co-Funding and Participating Institutes and Centres: NIAID, NCI, NICHD, NHLBI, NIDA, NIMHD, NIA, NIDDK, NIDCR, NIMH, NINR, NIGMS, and OD. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

History

Usage metrics

    Annals of Medicine

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC